Literature DB >> 23738566

JC viremia in natalizumab-treated patients with multiple sclerosis.

Eugene O Major, Elliot Frohman, Daniel Douek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23738566      PMCID： PMC3771634          DOI： 10.1056/NEJMc1214233

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.

Authors:  A K Trampe; C Hemmelmann; A Stroet; A Haghikia; K Hellwig; H Wiendl; S Goelz; A Ziegler; R Gold; A Chan
Journal:  Neurology       Date:  2012-05-16       Impact factor: 9.910

2.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

3.  JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.

Authors:  Caroline F Ryschkewitsch; Peter N Jensen; Maria Chiara Monaco; Eugene O Major
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

4.  Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Molly R Perkins; Caroline Ryschkewitsch; Julia C Liebner; Maria Chiara G Monaco; Danielle Himelfarb; Sara Ireland; Annelys Roque; Heather L Edward; Peter N Jensen; Gina Remington; Thomas Abraham; Jaspreet Abraham; Benjamin Greenberg; Charles Kaufman; Chris LaGanke; Nancy L Monson; Xiaoning Xu; Elliot Frohman; Eugene O Major; Daniel C Douek
Journal:  PLoS Pathog       Date:  2012-11-08       Impact factor: 6.823
  4 in total
  29 in total

1.  Immune reconstitution after allogeneic hematopoietic stem cell transplantation is associated with selective control of JC virus reactivation.

Authors:  Chen Sabrina Tan; Thomas A Broge; Long Ngo; Sarah Gheuens; Raphael Viscidi; Evelyn Bord; Jacalyn Rosenblatt; Michael Wong; David Avigan; Igor J Koralnik
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-27       Impact factor: 5.742

2.  JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.

Authors:  Spyridon Chalkias; Xin Dang; Evelyn Bord; Marion C Stein; R Philip Kinkel; Jacob A Sloane; Maureen Donnelly; Carolina Ionete; Maria K Houtchens; Guy J Buckle; Stephanie Batson; Igor J Koralnik
Journal:  Ann Neurol       Date:  2014-06-10       Impact factor: 10.422

3.  Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Benoit Combaluzier; Ilijas Jelcic; Wolfgang Faigle; Luzia Senn; Brenda J Reinhart; Luisa Ströh; Roger M Nitsch; Thilo Stehle; Mireia Sospedra; Jan Grimm; Roland Martin
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

Review 4.  Sorting out the risks in progressive multifocal leukoencephalopathy.

Authors:  Leonard H Calabrese; Eamonn Molloy; Joseph Berger
Journal:  Nat Rev Rheumatol       Date:  2014-10-14       Impact factor: 20.543

5.  No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan.

Authors:  D Focosi; L Macera; E Ciabatti; S Galimberti; M Petrini; A M Carella; M Pistello; L Ceccherini-Nelli; F Maggi
Journal:  Infection       Date:  2014-08-21       Impact factor: 3.553

6.  Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy.

Authors:  Leslie J Marshall; Michael W Ferenczy; Elizabeth L Daley; Peter N Jensen; Caroline F Ryschkewitsch; Eugene O Major
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 7.  Multiple sclerosis-a quiet revolution.

Authors:  Richard M Ransohoff; David A Hafler; Claudia F Lucchinetti
Journal:  Nat Rev Neurol       Date:  2015-02-17       Impact factor: 42.937

Review 8.  Immunology of progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Ilijas Jelcic; Wolfgang Faigle; Mireia Sospedra; Roland Martin
Journal:  J Neurovirol       Date:  2015-03-05       Impact factor: 2.643

Review 9.  Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

Authors:  Mark S Igra; David Paling; Mike P Wattjes; Daniel J A Connolly; Nigel Hoggard
Journal:  Br J Radiol       Date:  2017-04-26       Impact factor: 3.039

10.  JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.

Authors:  Serena Delbue; Francesca Elia; Camilla Carloni; Valentina Pecchenini; Diego Franciotta; Matteo Gastaldi; Elena Colombo; Lucia Signorini; Silvia Carluccio; Anna Bellizzi; Roberto Bergamaschi; Pasquale Ferrante
Journal:  J Neurovirol       Date:  2014-07-23       Impact factor: 2.643
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.